FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2209896411> ?p ?o ?g. }

• W2209896411 endingPage "445" @default.
• W2209896411 startingPage "434" @default.
• W2209896411 abstract "This study was undertaken to determine an immunologically active regimen for the administration of recombinant gamma-interferon (rIFN-gamma). The patient population included patients with completely resected melanoma, stage I (Clark's level IV or V) or stage II. All patients exhibited no evidence of disease (NED) at the time of the study. Patients received rIFN-gamma by intramuscular (IM) injection daily for 15 days at 0.0001 mg/m2, 0.001 mg/m2, 0.01 mg/m2, 0.1 mg/m2 (ten patients/group), or 0.25 mg/m2 (five patients). Interferon (IFN) was well tolerated, with non-dose-limiting constitutional symptoms occurring in the majority of patients at 0.1 mg/m2 and 0.25 mg/m2. All five patients receiving 0.25 mg/m2 developed elevated transaminase levels, which led to a discontinuation of therapy in one patient. Immunological activity was assessed by serial measurements of natural killer (NK) cell activity, hydrogen peroxide production by monocytes, and changes in expression of Fc receptors and human leukocyte class II antigen (HLA-DR) on monocytes. These changes were determined at baseline (X2), six to seven time points during rIFN-gamma therapy, and two times after the last dose of rIFN-gamma. No changes were observed at the two lowest doses. At the 0.01 mg/m2 dose, all parameters were elevated but not as consistently nor to the same levels as seen following administration of 0.1 mg/m2. At 0.25 mg/m2, H2O2 production was enhanced, but unlike at 0.1 mg/m2, it declined during the last few days of IFN therapy. Subcutaneous (SC) administration was compared with IM administration using the 0.1 mg/m2 dose. SC administration resulted in enhanced H2O2 production and Fc receptor expression by monocytes. More consistent elevations in peroxide generation and higher levels of Fc receptor expression were seen following SC administration. No significant difference was found between the two routes of administration. A comparison of two schedules, daily and three times weekly, suggested that monocyte activation may return to normal 72 hours after IFN administration. Of the doses tested, 0.1 mg/m2 administered daily appeared to be the most effective biological response modifier (BRM) regimen, and because of ease of administration, we favor the SC route." @default.
• W2209896411 created "2016-06-24" @default.
• W2209896411 creator A5014063407 @default.
• W2209896411 creator A5015558009 @default.
• W2209896411 creator A5025100380 @default.
• W2209896411 creator A5039707350 @default.
• W2209896411 creator A5043071839 @default.
• W2209896411 creator A5045058182 @default.
• W2209896411 creator A5052886428 @default.
• W2209896411 creator A5061974815 @default.
• W2209896411 creator A5063710981 @default.
• W2209896411 creator A5072866478 @default.
• W2209896411 date "1988-03-01" @default.
• W2209896411 modified "2023-09-24" @default.
• W2209896411 title "The determination of an immunologically active dose of interferon-gamma in patients with melanoma." @default.
• W2209896411 cites W1491325575 @default.
• W2209896411 cites W1501348451 @default.
• W2209896411 cites W1571681582 @default.
• W2209896411 cites W1645358757 @default.
• W2209896411 cites W1927697103 @default.
• W2209896411 cites W1979065792 @default.
• W2209896411 cites W1997652060 @default.
• W2209896411 cites W1999912471 @default.
• W2209896411 cites W2019150375 @default.
• W2209896411 cites W2022515405 @default.
• W2209896411 cites W2051032788 @default.
• W2209896411 cites W2055092075 @default.
• W2209896411 cites W2067609410 @default.
• W2209896411 cites W2088740471 @default.
• W2209896411 cites W2126204744 @default.
• W2209896411 cites W2160040629 @default.
• W2209896411 cites W2283463817 @default.
• W2209896411 cites W2340679956 @default.
• W2209896411 doi "https://doi.org/10.1200/jco.1988.6.3.434" @default.
• W2209896411 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3127550" @default.
• W2209896411 hasPublicationYear "1988" @default.
• W2209896411 type Work @default.
• W2209896411 sameAs 2209896411 @default.
• W2209896411 citedByCount "121" @default.
• W2209896411 countsByYear W22098964112013 @default.
• W2209896411 countsByYear W22098964112015 @default.
• W2209896411 countsByYear W22098964112022 @default.
• W2209896411 crossrefType "journal-article" @default.
• W2209896411 hasAuthorship W2209896411A5014063407 @default.
• W2209896411 hasAuthorship W2209896411A5015558009 @default.
• W2209896411 hasAuthorship W2209896411A5025100380 @default.
• W2209896411 hasAuthorship W2209896411A5039707350 @default.
• W2209896411 hasAuthorship W2209896411A5043071839 @default.
• W2209896411 hasAuthorship W2209896411A5045058182 @default.
• W2209896411 hasAuthorship W2209896411A5052886428 @default.
• W2209896411 hasAuthorship W2209896411A5061974815 @default.
• W2209896411 hasAuthorship W2209896411A5063710981 @default.
• W2209896411 hasAuthorship W2209896411A5072866478 @default.
• W2209896411 hasConcept C126322002 @default.
• W2209896411 hasConcept C203014093 @default.
• W2209896411 hasConcept C2777658100 @default.
• W2209896411 hasConcept C2778690821 @default.
• W2209896411 hasConcept C2778715236 @default.
• W2209896411 hasConcept C2780567839 @default.
• W2209896411 hasConcept C2780841837 @default.
• W2209896411 hasConcept C2781413609 @default.
• W2209896411 hasConcept C2908647359 @default.
• W2209896411 hasConcept C29730261 @default.
• W2209896411 hasConcept C502942594 @default.
• W2209896411 hasConcept C71924100 @default.
• W2209896411 hasConcept C90924648 @default.
• W2209896411 hasConcept C99454951 @default.
• W2209896411 hasConceptScore W2209896411C126322002 @default.
• W2209896411 hasConceptScore W2209896411C203014093 @default.
• W2209896411 hasConceptScore W2209896411C2777658100 @default.
• W2209896411 hasConceptScore W2209896411C2778690821 @default.
• W2209896411 hasConceptScore W2209896411C2778715236 @default.
• W2209896411 hasConceptScore W2209896411C2780567839 @default.
• W2209896411 hasConceptScore W2209896411C2780841837 @default.
• W2209896411 hasConceptScore W2209896411C2781413609 @default.
• W2209896411 hasConceptScore W2209896411C2908647359 @default.
• W2209896411 hasConceptScore W2209896411C29730261 @default.
• W2209896411 hasConceptScore W2209896411C502942594 @default.
• W2209896411 hasConceptScore W2209896411C71924100 @default.
• W2209896411 hasConceptScore W2209896411C90924648 @default.
• W2209896411 hasConceptScore W2209896411C99454951 @default.
• W2209896411 hasIssue "3" @default.
• W2209896411 hasLocation W22098964111 @default.
• W2209896411 hasLocation W22098964112 @default.
• W2209896411 hasOpenAccess W2209896411 @default.
• W2209896411 hasPrimaryLocation W22098964111 @default.
• W2209896411 hasRelatedWork W2021968456 @default.
• W2209896411 hasRelatedWork W2068861579 @default.
• W2209896411 hasRelatedWork W2085208618 @default.
• W2209896411 hasRelatedWork W2125155221 @default.
• W2209896411 hasRelatedWork W2412245334 @default.
• W2209896411 hasRelatedWork W2466043692 @default.
• W2209896411 hasRelatedWork W2981372661 @default.
• W2209896411 hasRelatedWork W3044777183 @default.
• W2209896411 hasRelatedWork W3127681959 @default.
• W2209896411 hasRelatedWork W4254658616 @default.
• W2209896411 hasVolume "6" @default.
• W2209896411 isParatext "false" @default.

• next